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Abstract
Pulmonary hypertension (PH) is a chronic disease characterized by vasoconstriction and cell 
proliferation in the pulmonary vasculature and defi nes as an elevation of mean pulmonary 
arterial pressure more than 25 mmHg as assessed by right heart catheterization. According to 
the classifi cation of pulmonary hypertension by World Symposium of Pulmonary Hypertension 
(WSPH) 2013, PH is divided into fi ve groups. Pulmonary Arterial Hypertension (PAH) is group 1 
of PH Classifi cation. The clinical classifi cation of PH into fi ve groups is according to their similar 
clinical presentation, pathological fi ndings, hemodynamic characteristics and treatment strategy. 
Congenital heart disease is one of disease that associate with the development of PAH. 
The Jogjakarta Congenital Heart Disease-Pulmonary Hypertension (COHARD-PH) study is a 
registry of Adult Congenital Heart Disease (ACHD) and PH in Dr. Sardjito Hospital Yogyakarta 
Indonesia, which is a national referral hospital in the region. The COHARD-PH has been 
conducted since 5 years ago and until currently there are 696 ACHD patients enrolled. The 
population of COHARD-PH registry is predominantly woman patients and young age with 
less than 40 years old. Most of the patients have already suffered from PH (70%) that is 
diagnosed by right heart catheterization (RHC). The utility of RHC itself to diagnose PAH, 
based on guideline, is only available in our hospital in the region. 
The high prevalence of ACHD in Yogyakarta region and surrounding area coming to our hospital 
due to PH sign and symptom is a concern. The region with limited facility to diagnose and 
availability of drugs urges us to make strategy to detect the CHD in the earliest.  A preventive 
policy such as screening of CHD as early as possible so that the case fi nding will increase 
and a proposal to the government to fully provide the availability of PH drugs in those affected.  
The strategies may be effective in reducing morbidity and mortality of the disease and also 
increasing quality of life for the patients.  
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